ArticleJournal of extracellular biology2026
Development of a Novel Extracellular Vesicle-Based Biomarker Approach for Pediatric High-Grade Glioma.
Article in Journal of extracellular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Extracellular Vesicles as a Potential Tool in Cancer Diagnosis and Therapy.Biomedicines · 2026Review
- Extracellular Vesicles in the Biology and Liquid Biopsy Diagnostics of Pediatric High-Grade Glioma - Emerging Findings and Opportunities.Journal of extracellular biology · 2026Review
- Development of a Novel Extracellular Vesicle-Based Biomarker Approach for Pediatric High-Grade Glioma.Journal of extracellular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Pediatric high-grade gliomas (pHGGs) account for 20% of childhood brain tumours and are associated with poor survival. Currently, pHGG detection relies on MRI, a costly and time-consuming procedure. Extracellular vesicles (EVs) carry molecular markers indicative of their cellular origin and can be isolated from various biofluids, offering an alternative approach. Recent studies showed that pHGGs contain cells that molecularly and morphologically resemble radial glia (RG), a type of neural progenitor. Given that RGs are normally exclusive to the developing brain, we hypothesized that EVs secreted from RG-like glioma cells serve as a pHGG biomarker. However, there are no established molecular markers to specifically detect RG-derived EVs. To address this, we first identified a combination of surface markers to differentiate EVs derived from RG-like glioma cells from those of non-RG cells. We next validated the expression of these markers in patient-derived cell lines. Analysis of EVs isolated from cell culture media confirmed the presence of these markers, along with other tumour-associated markers including targets of chimeric antigen receptor (CAR) T cell therapy. Taken together, our results showed that RG-derived EVs can be isolated and detected by the combination of markers, laying a groundwork for developing a novel EV-based biomarker for pHGGs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.